+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
ID06980597

Phase 1 Study of OL-108 CAR-T Cell Therapy for Adults with Relapsed or Refractory Autoimmune Diseases Including SLE, IIM, SSc, and AAV

Led by Beijing GoBroad Hospital · Updated on 2025-05-20

44

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, pharmacokinetics, and early effects of OL-108, an allogeneic CAR-T cell therapy, in adults with relapsed or refractory autoimmune diseases such as systemic lupus erythematosus SLE, idiopathic inflammatory myopathy IIM, systemic sclerosis SSc, and ANCA-associated vasculitis AAV. This open-label, single-arm clinical trial aims to understand how OL-108 works in these conditions and to assess any side effects. Participants will receive OL-108 through an intravenous bolus at increasing dose levels to find the maximum tolerated dose. The study includes a phase of lymphodepletion before OL-108 administration. The trial monitors the treatment from the start through up to two years to evaluate safety, immune response, and drug levels in the body. No placebo or comparison group is involved. During the study, participants will undergo regular assessments including monitoring for dose-limiting toxicities and treatment-related adverse events up to 30 days and two years respectively. Researchers will measure overall response rates, drug concentration peaks and durations, serum cytokines, immunogenicity, and replication-competent retrovirus levels. Safety and treatment effects will be carefully tracked throughout the study period, which may last up to two years after dosing.

CONDITIONS

Brief Title

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

Research Team

K

Kai Hu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here